Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial

03.10.2023 - Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level

Related Keywords

Shawn Iadonato ,Nasdaq ,Kineta Inc ,Chief Executive Officer ,Kineta Chart ,Ineta Kurs ,Ineta Aktie ,